Aelix Therapeutics, a CataloniaBio & HealthTech member that Ysios Capital holds a stake in, has named Melanie Rolli its new CEO, taking over for José Luis Cabero.
This change comes after announcing, this past March, the positive results of the Phase I/II clinical trial on its HIV vaccine, which will help support future development of therapeutic strategies to control the disease without having to turn to ongoing antiretroviral therapy.
Melanie Rolli has a PhD in Pharmacology from Heidelberg University (Germany). From 2017 to 2021, she was CEO of Piqur Therapeutics AG in Basel (Switzerland). Previously, she spent 14 years at Novartis in various positions of responsibility in global development, safety, and medical management.
You may also be interested in:
Catalan HIV vaccine shows positive results in first clinical trial
Comments